Blood tests (also called liquid biopsies), designed to identify the presence of multiple cancers before symptoms occur, are beginning to become reality in the UK. They offer the opportunity to screen for and diagnose cancer earlier, potentially increasing the range of treatment options and improving long-term survival rates.
In this session experts in the prevention and early diagnosis of cancer will discuss the potential of multi-cancer early detection (MCED) tests. Researchers will share their views and lessons from studies such as SYMPLIFY, in which an MCED test is being used to detect more than 50 types of cancer in patients with non-specific symptoms. They will also discuss the views of cancer patients and public attitudes to this type of testing before taking part in a panel discussion and Q&A.
By the end of the session, attendees will have a better understanding of the potential of MCED tests to reduce the burden of cancer. Attendees will have learnt lessons from existing trials as well as understood the views of patients and the public.
- Professor Emma Crosbie – University of Manchester and Deputy Chair of NCRI Screening, Prevention & Early Diagnosis Group, UK
- Ms Sue Duncombe – NCRI Consumer Forum and PPI contributor, UK
- Dr Catherine Elliott – Cancer Research UK, UK
- Dr Laura Marlow – King’s College London, UK
- Professor Mark Middleton – University of Oxford, UK
- Dr Louise Medley – Torbay and South Devon NHS Foundation Trust, UK
- Professor Peter Sasieni – King’s College London and Chair of NCRI Screening, Prevention & Early Diagnosis Group, UK
2 category 1 (external) CPD credits for this session have been approved by the Federation of the Royal Colleges of Physicians. Delegates requiring a CPD certificate can add this during the registration process for a charge of £15. CPD Certificates will be sent automatically up to 10 days after the event date.
Who should attend?
Anyone interested or working in screening, prevention and early diagnosis of cancer including patients and carers formally involved in research, scientists, medical/clinical oncologists, surgeons, early career researchers, nurses, allied health professionals, PhD and undergraduate students, research teams and research managers/funders.